Georgian Partners leads growth round
Funds to expand market access and expand data analytics capabilities

MOUNTAIN VIEW, Calif., June 27, 2017 — Glooko, the leader in diabetes data management, today announced $35 million in new funding to accelerate growth, expand international presence, and deepen expertise in data analytics. This round was led by Georgian Partners, a Toronto-based investor focused on applied analytics and machine learning. Other new investors include Insulet Corporation and Mayo Clinic who join existing investors Canaan Partners, Social Capital, Medtronic and Samsung NEXT in the round.

Glooko will use the funds to accelerate growth by expanding its sales, marketing and development teams. The company will also increase commercialization efforts in France, Germany, the U.K., Asia and the Middle East, and further development efforts in data analytics and artificial intelligence to provide personalized insights that drive meaningful behavior change.

“Glooko has demonstrated great traction and growth. Its scalable, device-agnostic platform not only meets the needs of people with diabetes, it also benefits health insurance plans, employers, pharma and health systems that want to effectively manage large populations of people with diabetes,” said Simon Chong, managing director at Georgian Partners. “We are excited to become a part of the Glooko investment team, working with Glooko on its analytics-driven approach to delivering both personal and clinical support to the diabetes community.”

Glooko’s diabetes data management solutions help more than one million patients served by 6,000+ providers and a growing number of health plans around the world. Glooko provides payers, employers, pharmaceutical companies and health systems with a diabetes digital health platform that deliver personalized and actionable insights to people with diabetes and their care teams that aim to drive improved outcomes at a lower cost.

Glooko’s demonstrated improvements in outcomes to manage diabetes are part of a larger effort to combat the growing epidemic. Globally, the cost of diabetes has risen to $825 billion a year and the number of adults with diabetes reached 422 million worldwide in 2016. Without systemic changes to diabetes management, this number could grow to 700 million by 2025, according to a study reported in The Lancet.

“This additional funding will help us to further our mission: to improve the lives of people with diabetes,” said Rick Altinger, CEO of Glooko. “With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits.”

About Glooko
More than one million people trust Glooko to help manage their diabetes. Glooko’s FDA-cleared, HIPAA-compliant platform supports more than 6,000 providers in 27 countries. Glooko strives to improve health outcomes with innovations in diabetes data analytics and artificial intelligence. Glooko’s mobile and web apps and clinic upload solutions sync with the world’s most popular diabetes devices, fitness wearables and activity trackers to enable easy data capture and provides reports and analytics that aim to drive behavior change and outcomes. For more information visit: glooko.com,Facebook, Twitter, LinkedIn, YouTube.

About Georgian Partners
Georgian Partners is a thesis-driven growth equity firm investing in SaaS-based business software companies exploiting applied artificial intelligence, security first and conversational business. Founded by successful entrepreneurs and technology executives, Georgian Partners leverages our global software expertise to be able to directly impact the success of companies. For more information, visit www.georgianpartners.com.

Press Contacts

Vikram Singh – [email protected], Glooko, PR

Dana Schroeder – [email protected], Sterling Communications

PRM # 0401

Poster to be presented at the 77th Annual ADA Meeting, June 9-13, 2017 in San Diego, CA

Mountain View, California –June 9, 2017, Glooko, the leader in diabetes data management today announced the results of two retrospective studies that examine the clinical impact of use of its diabetes management mobile application. The studies found that using the Glooko mobile app was associated with a drop in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes. Furthermore, usage of the Glooko mobile application was also associated with an increase in blood glucose test rate. Increased blood glucose testing rates have been shown to directly correlate with improvements in glycemic control, as evidenced by this retrospective study and other studies as well.

“We are thrilled to see this additional clinical evidence that shows the positive impact Glooko can have on people with diabetes,” Rick Altinger, CEO of Glooko said. “Glooko’s mission has always been to improve the clinical outcomes for people with diabetes by making diabetes management easier through digital tools. Our user satisfaction rates coupled with this clinical evidence adds credence to the investments that digital health companies have been making to improve the lives of people with chronic diseases.”

The Glooko mobile app users in these studies were, on average, already managing diabetes adequately (below 8% eA1c). After starting on Glooko the users showed further improvement. The retrospective studies show that Glooko mobile app users who used the app for self-management experienced the following clinical results compared to a control group of users who did not use the Glooko mobile app, but did upload their data in the clinic:

For more information about the results of these studies, download the poster presented at the Diabetes Technology Society or come see our most recent poster with updated data at the ADA in San Diego, from June 9-13, 2017 in location 880-P. In addition, Glooko will be demonstrating the Glooko + Diasend integrated product line in booth #2143 at this year’s ADA event.

©2017 Glooko, Inc. Glooko and Diasend is a trademark of Glooko, Inc. All rights reserved. PRM 0400 Rev A

Expanded integration enables on-demand access to CGM data for people with diabetes and care teams to optimize care plans

Mountain View, CA – June 1, 2017, Glooko, the leader in diabetes data management, today announced an expanded agreement with Dexcom, the leader in Continuous Glucose Monitoring (CGM) for people with diabetes. Rather than requiring Dexcom devices to be proactively synced to Glooko via a cable or connection to Apple Health, this expanded relationship will deliver Dexcom CGM data from all currently available Dexcom CGM systems into Glooko’s platform via the cloud. The cloud integration empowers people with diabetes and their care teams to optimize diabetes support by enabling passively collected, on-demand access to CGM data through the widely used Glooko platform.

“With this expanded relationship and ease of delivering Dexcom CGM data into Glooko, clinicians have additional options available to make better and faster treatment decisions,” said Steve Pacelli, Executive Vice President of Strategy and Corporate Development, Dexcom. “Glooko’s extensive clinical presence and use by people with diabetes globally make it an obvious choice to strengthen our partnership.”

Dexcom’s cloud infrastructure is designed to give people with diabetes easy access to their CGM data and control over who they share it with, so they can enhance both their self-management and clinic-based care. This relationship builds on Glooko’s continued dedication to liberating diabetes data to help improve daily decision making for people with diabetes and their care teams.

“We are thrilled to expand our partnership with Dexcom and provide our over 6,000 clinic users and 1 million patients globally better and faster access to their Dexcom CGM data,” said Rick Altinger, CEO, Glooko. “Having Dexcom CGM data, combined with food, medication and exercise data in Glooko, enables us to pinpoint behaviors and personalize insights to drive behavior change and ultimately improved outcomes.”

Dexcom G5 Mobile CGM data will be available for patients to sync to Glooko this summer and via Glooko’s Office Upload products (The Glooko Kiosk, The Glooko Clinic Uploader and the Glooko Transmitter) in the US this month. It is already available in the EU through Glooko’s office upload product, Diasend. The expanded cloud integration with Dexcom will be available globally later this year in Glooko.

For more information visit: glooko.com, Facebook, Twitter, LinkedIn, YouTube.

PRM 0399

Partnership to marry technology platform with human coaching, aims to improve outcomes for patients and care teams

Mountain View & New York, New York, California, April 27, 2017 – Fit4D, a diabetes patient engagement solution, announced a partnership today with Glooko, a global diabetes data management company, to deliver highly personalized, data-driven coaching and a mobile health solution to patients and care providers.

The Glooko/Fit4D collaboration, which leverages user-specific data for timely and customized interventions, aims to improve health outcomes, reduce costs, and enhance patient-coach relationships. Combining Fit4D’s clinically expert coaches with Glooko’s device agnostic technology platform creates one of the marketplace’s most scaleable, integrated diabetes management offerings.

“We always look for ways to deliver better support to our patients, so we are excited to partner with Glooko,” said David Weingard, CEO of Fit4D. “Glooko’s mobile solution, providing access to glycemic data, complemented with contextualized lifestyle tracking, provides Fit4D even more insight into how our patients are doing so we can provide them with the support they need, when they need it most.”  Weingard shares, “With the Glooko collaboration, Fit4D can offer a comprehensive patient engagement solution that delivers on positive patient experience, an opportunity to strengthen brand loyalty for our pharma clients, while creating value to payers, providers, and employers seeking to provide services to individuals with chronic diseases, like diabetes.”

Glooko enables Fit4D to extend the impact of personal coaching through data and insights while Fit4D provides Glooko patients and clients with the turnkey “human touch” component that drives sustained behavior change. Glooko’s mobile app enables people with diabetes to automatically sync their blood glucose data from over 95% of the blood glucose meters, CGMs and insulin pumps available on formulary and then augment that data with food, exercise and medication data. That data is then made available to Fit4D coaches through the Glooko Population Tracker.

With the support of Fit4D clinical educators, patients will receive additional motivation and education to engage more meaningfully with the Glooko platform – from how to sync their data to understanding what their data means to them.

“Fit4D’s depth of clinical experience and years of diabetes expertise extends the value of the Glooko diabetes management platform and offers organizations without coaching an integrated diabetes management solution,” said Rick Altinger, CEO of Glooko. “Combining the quantitative data from Glooko with the expert coaching and qualitative data on patient barriers and confidence from Fit4D allows us to jointly provide a flexible end-to-end solution that provides important and relevant support to people with diabetes.”

Fit4D is a technology-enabled health coaching solution that scales the ability of expert certified diabetes educators (CDEs), to reach and engage patients. Fit4D clients include pharmaceutical companies with a branded drug or device seeking to improve initiation and adherence, and payers looking to improve health outcomes and quality measures.

The company’s team of CDEs across the country leverage the Fit4D technology platform to engage patients with personalized plans that address the individual barriers one faces when learning to self-manage the condition. Coaching topics include diabetes education, tips and tactics to initiate therapy and improve medication adherence, the importance of preventive care, nutrition, exercise, advice to overcome psychosocial barriers, weight management and more.

Glooko’s diabetes management solution offers mobile and web based tools that sync with patients’ preferred diabetes devices – no switching needed. Powerful algorithms that identify important glucose trends and the ability to correlate the impact of food, activity and other lifestyle choices on glucose values give Glooko patients and the thousands of care teams who use Glooko, the insights they need to make better decisions.

About Fit4D
Fit4D’s mission is to enrich the lives and the improve health outcomes of people living with diabetes and other chronic diseases worldwide. Fit4D delivers scalable and cost-effective personalized patient programs using a technology platform to optimize the mix of digital and human-based touch points. The Fit4D clinical team of certified diabetes educators (CDEs) is comprised of dietitians, exercise physiologists, nurses, and social workers, who are passionate about empowering people with diabetes to live rich, healthy and fulfilling lives.

Fit4D’s Fortune 500 clients include pharmaceutical, payer, provider and wellness companies. Fit4D has also engaged in numerous joint initiatives with the Juvenile Diabetes Research Foundation, American Diabetes Association, and the Diabetes Research Institute.

Fit4D is also a Startup Health transformer company. For more information, visit: www.fit4d.com.

About Glooko
Glooko is the leading diabetes management solution and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and insightful reports, graphs and risk flags to health systems and payers. For more information, visit: www.glooko.com

PRM 0370

Basel, Switzerland and Mountain View, CA 31 January 2017 – Ascensia Diabetes Care and Glooko, Inc today announced a global technology partnership designed to bring together their state-of-the-art diabetes management solutions, and improve diabetes data management and analytics. This collaboration includes integration of Glooko’s Diabetes Data Management Platform and Ascensia’s CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems. The integration of these solutions will allow people with diabetes and health care professionals to access and analyze highly accurate blood glucose data at home, on the move and during office visits through the digital platform of their choice.

“Glooko’s Diabetes Data Management Platform has become widely used for both personal and clinical diabetes data analytics and decision support,” said Michael Kloss, CEO of Ascensia Diabetes Care. He continued, “Glooko’s broad distribution into health systems will enable us to easily and seamlessly deliver highly accurate data from our CONTOUR NEXT®ONE and CONTOUR®PLUS ONE blood glucose monitoring systems to clinicians right in their workflow. By linking our systems to Glooko’s Diabetes Data Management Platform, we want to enable better understanding and analysis of diabetes data, and ultimately help to improve the lives of people with diabetes.”

The integration of these solutions will allow blood glucose data to be accessed by Glooko’s Mobile App and Clinic Data Upload products directly from the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE meters via Bluetooth® connectivity and through an automatic feed via the CONTOUR CLOUD. People with diabetes will be able to view their data both in Glooko’s Mobile and Web Apps, as well as in the CONTOUR™ DIABETES App from Ascensia. Health care professionals will be able to seamlessly access data from these two Ascensia systems in a way that fits directly into their workflow via the Glooko Clinic Solution.

“The usability and accuracy of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems from Ascensia Diabetes Care is impressive and we are excited to bring this rich data into the Glooko platform to help both people with diabetes and their health care professionals manage this condition,” said Rick Altinger, Glooko CEO.

The CONTOUR®NEXT ONE system recently received 510(k) clearance from the FDA and Ascensia Diabetes Care expects to make this system available in the United States in early 2017. The CONTOUR™ DIABETES app will be available for download from the Apple App Store (iOS) and Google Play (Android). The CONTOUR®NEXT ONE and CONTOUR®PLUS ONE systems have been demonstrated to be the two most accurate systems developed by Ascensia Diabetes Care to date, having been shown to deliver remarkable accuracy. In a clinical study, 95% of blood glucose results obtained with CONTOUR®NEXT ONE were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests.1 In a similar clinical study, 95% of blood glucose results for CONTOUR®PLUS ONE were within 8.5 mg/dL (0.5 mmol/L) or 8.5% of the reference result for subject fingertip tests.2

Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko’s award-winning mobile health app enables individuals to synchronize their data from a majority of the world’s most popular diabetes and exercise devices including blood glucose meters. Glooko’s population health application enables care teams to remotely support people with diabetes and aims to improve patient satisfaction and outcomes at a lower cost.

This global agreement covers all markets where Glooko and these Ascensia systems are available. The integration between these two solutions is expected to be available for people with diabetes and health care professionals later in 2017.

ENDS

Notes for Editors

About Glooko
Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Over 4,800 health systems in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes and to enable diabetes population health for providers. Glooko seamlessly syncs with the world’s most popular diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. For more information visit: glooko.com, Facebook, Twitter, LinkedIn, YouTube.

About Ascensia Diabetes Care
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR™ portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 38 countries.

For further information please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

2017 Ascensia Diabetes Care. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. Glooko is a registered trademark of Glooko, Inc.

The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license.

Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Google Play is a trademark of Google Inc.
For more information please contact:

Joseph Delahunty, VP, Global Head of Communications

Ascensia Diabetes Care

E-mail: [email protected]

Phone: +41 79 422 9286

Vikram Singh, Marketing Manager

Glooko

E-mail: [email protected]

Phone: +1 650 720 5310

References

1.Christiansen et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.

2.Bailey et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.

Bagsværd, Denmark and Mountain View, California, 9 January 2017
Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data analytics expertise.

Building on Glooko’s mobile and web platforms, the companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. The partnership’s joint offerings will also assist healthcare professionals to engage and manage patients with the aid of population-wide data reporting. By integrating these offerings within its Digital Health Platform developed with IBM Watson Health, Novo Nordisk aims to generate increasingly valuable insights into diabetes management and treatment outcomes.
Commenting on the agreement, Christian Kanstrup, senior vice president, Strategy, Access & Marketing, Novo Nordisk said: “We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control. Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko’s award-winning mobile health app enables individuals to synchronise their data from a majority of the world’s most popular diabetes and exercise devices including blood glucose meters. Glooko’s population health application enables care teams to remotely support people with diabetes and aims to improve patient satisfaction and outcomes at a lower cost.

“Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier”, said Rick Altinger, Glooko CEO. “We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”

 

<strong>About Novo Nordisk</strong>

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 75 countries and markets its products in more than 180 countries. For more information, visit <a href=”http://novonordisk.com” target=”_blank”>novonordisk.com</a>, <a href=”http://www.facebook.com/novonordisk”>Facebook</a>, <a href=”http://www.twitter.com/novonordisk”>Twitter</a>, <a href=”http://www.linkedin.com/company/novo-nordisk”>LinkedIn</a>, <a href=”http://www.youtube.com/novonordisk”>YouTube</a>

<strong>About Glooko</strong>

Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Over 4,800 health systems in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes and to enable diabetes population health for providers. Glooko seamlessly syncs with the world’s most popular diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. For more information visit: <a href=”https://glooko.com/”>glooko.com</a>, <a href=”https://www.facebook.com/Glooko/”>Facebook</a>, <a href=”https://twitter.com/GlookoInc”>Twitter</a>, <a href=”https://www.linkedin.com/company/Glooko”>LinkedIn</a>, <a href=”https://www.youtube.com/user/GlookoInc”>YouTube</a>.

 

<strong>Further information</strong>

<em>Novo Nordisk Media:</em>

Adam Pittard                        +45 3075 5056       <a href=”mailto:[email protected]” target=”_blank”>[email protected]</a>

Ken Inchausti (US)             +1 609 786 8316    <a href=”mailto:[email protected]”>[email protected]</a>

 

<em>Glooko Media:</em>

Vikram Singh                       +1 650 720 5310    <a href=”mailto:[email protected]”>[email protected]</a>

 

<em>Novo Nordisk Investors:</em>

Peter Hugreffe Ankersen   +45 3075 9085      <a href=”mailto:[email protected]”>[email protected]</a>

Melanie Raouzeos               +45 3075 3479      <a href=”mailto:[email protected]”>[email protected]</a>

Hanna Ögren                        +45 3079 8519       <a href=”mailto:[email protected]”>[email protected]</a>

Anders Mikkelsen                +45 3079 4461       <a href=”mailto:[email protected]”>[email protected]</a>

Kasper Veje (US)                 +1 609 235 8567     <a href=”mailto:[email protected]”>[email protected]</a>

 

<em>Glooko Investors:</em>

Michelle de Haaff                +1 650 720 5310   <a href=”mailto:[email protected]”>[email protected]</a>

 

PRM 0301 Rev A

FREE Webinar on October 24, 2016 provides an overview of their digital diabetes program powered by Glooko

Mountain View, California and Gothenburg, Sweden –October 21, 2016 – Atrius Health has always been an innovator when it comes to providing services to their patients. They are a national leader in clinical quality and electronic patient record use, and are a Pioneer Accountable Care Organization with approximately 75% of their revenue generated through risk based contracts.  Atrius Health has successfully implemented Glooko as their diabetes remote patient monitoring solution, which includes an integration with their electronic health record (EHR) system.

“For us, Glooko provides the ability to enable our teams to easily provide remote support to the patients we serve with diabetes,” said Dr. Michael Lee, Senior Medical Director of Clinical Informatics at Atrius Health. In a recent program using Glooko, Atrius Health saw positive outcomes for people with gestational diabetes. Using Glooko, they were able to more effectively manage and support women diagnosed with diabetes while pregnant.

Dr. Lee continues, “Glooko makes it easy for patients to capture their diabetes, exercise, diet and medication data and immediately share that with our population health staff allowing us to provide preventative and in-between visit care to optimize the care plan and prevent acute situations.”

In a webinar on October 24, 2016, Atrius Health will discuss how they use the Glooko Population Health Management and Mobile Health system to better serve people with diabetes.

Jennivine Lee Simon, Director of Marketing at Glooko will be joined by Dr. Michael Lee, Senior Medical Director of Clinical Informatics at Atrius Health to discuss why Atrius decided to implement remote patient monitoring, how they selected Glooko, the EHR integration process and their lessons learned.  This webinar will also include a live Q&A session with Dr. Lee.

Link here to register to attend this FREE webinar. Those who register will also gain access to a recording of the event.

About Glooko
Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at www.glooko.com and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko.
©2016 Glooko, Inc. Glooko is a trademark of Glooko, Inc. Other brand names may be trademarks of their respective owner(s). Information is subject to change without notice. All rights reserved.

Partnership provides bring your own device ‘BYOD’ virtual care solution to patients with diabetes

New York, New York and Mountain View, California – July 7, 2016 – AMC Health, the leading provider of proven remote patient monitoring and engagement solutions that are exclusively endorsed by the American Hospital Association, and Glooko Inc., the leading population health platform for diabetes management, today announced a partnership to help clinicians and patients improve diabetes outcomes at lower costs.

Glooko is one of many FDA 510(k) cleared devices now integrated into AMC Health’s expanding FDA-cleared CareConsole® virtual care platform. Glooko is currently being used in 1,000+ health systems, health plans and employers in the USA, including Joslin Diabetes Center, Stanford Health, and Atrius  Health in Boston. Glooko’s HIPAA-compliant solution enables easy downloading of information from over 50 of the most popular blood glucose meters, insulin pumps, and continuous glucose monitors (CGMs). Glooko enables individuals to download and add context to their data through its award-winning diabetes mobile application. Adding Glooko to the AMC Health CareConsole® platform with robust decision support analytics provides healthcare organizations tools to better optimize their clinical impact in diabetes populations.

“Glooko will be joining AMC Health’s extensive ecosystem of healthcare technology partners that have chosen to integrate into AMC Health’s CareConsole® virtual care platform. This partnership with Glooko will give patients the flexibility of using their existing glucometers and support stronger connections with their clinical teams on a real-time basis, while also expanding care beyond the walls of hospitals, doctors’ offices and outpatient settings,” said Nesim Bildirici, founder and CEO of AMC Health. “Our clinically proven solutions, and clinical, technology and analytics expertise, gained over millions of patient days, ensure that our solutions promote patient engagement, improve patient outcomes, and prevent costly acute episodes.”

AMC Health has been performing groundbreaking work in remote patient monitoring and engagement since its founding in 2002, and has consistently partnered with organizations to assist with the identification of patients with the highest risks, likelihood of hospitalizations, and utilization of services. AMC Health has demonstrated, in peer-reviewed clinical studies , that its remote patient monitoring and engagement solutions have reduced hospital readmissions for patients with heart failure and reduced their cost of care. AMC Health solutions have also helped patients with diabetes significantly reduce their HbA1c levels and patients with hypertension substantially reduce and control their blood pressure. These results have been published in the Journal of the American Medical Association (JAMA), Journal of Managed Care Medicine , Medical Care and Population Health Management.

“Glooko’s partnership with AMC Health means health systems, health plans, and employers will be able to ramp diabetes-focused programs using Glooko more quickly by leveraging AMC Health’s remote monitoring & population management expertise” said Rick Altinger, Glooko’s CEO. “Organizations using AMC Health’s suite of disease management tools addressing heart disease, hypertension and obesity can now access Glooko’s best-in-class platform for remotely monitoring blood glucose, a key biometric in managing those conditions.”

About AMC Health
AMC Health is the leading provider of virtual care solutions. AMC Health customers use these proven solutions to promote patient engagement, improve patient outcomes, and prevent costly acute episodes. AMC Health’s FDA-cleared remote patient engagement solution is powered by CareConsole®, an open web-based platform, which integrates seamlessly with biometric monitoring devices and other technologies so a care team can monitor patients’ chronic conditions and adherence to a care plan wherever they might be. Our customers have demonstrated through large published peer-reviewed studies across various disease states that outcomes can be improved significantly through connecting patients to their clinical teams on a real-time basis and expanding care beyond the walls of hospitals, doctors’ offices and outpatient settings. The published studies highlight improved care management, reduced medical costs and hospital readmissions, and a 3:1 or greater return on investment. AMC Health’s remote patient monitoring and engagement solutions have earned the exclusive endorsement of the American Hospital Association. For more information, visit www.amchealth.com.

About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com, and follow us at twitter.com/GlookoInc and facebook.com/Glooko.

Tweet this: @AMCHealth and @GlookoInc partnership provides #BYOD #virtualcare solution to improve diabetes outcomes | #remotepatientmonitoring #telehealth

Contacts:
Tanya L. Travers
917-757-9751
[email protected]
Vikram Singh
925-487-1461
[email protected]

Upon release Medtronic users and clinicians will have access to retrospective data insights from their Medtronic devices using Glooko’s Mobile and In-Clinic Apps

Mountain View, Calif. – June 10, 2016 – Glooko Inc., the leading unified platform for diabetes management, today announced compatibility with Medtronic MiniMed ® insulin pumps and sensors. Glooko will demonstrate the integrated solution at the 76th Annual Scientific Sessions of the American Diabetes Association from June 10 – 13, 2016 in New Orleans. The integrated solution highlights optimized workflows for both patients and clinics in downloading data from Medtronic insulin pumps and continuous glucose monitoring (CGM) sensors. In addition, it offers the ability to analyze the correlation of insulin data with blood glucose readings from over 50+ blood glucose meters, continuous glucose monitors (CGMs) as well as from exercise and biometric devices.

“By integrating into the Glooko diabetes management platform, we now provide safe and secure access to meaningful diabetes information, beyond just device data, and new disease management solutions. Our partnership with Glooko reflects our overall strategy to become a holistic diabetes management company and provide new solutions for people with diabetes, for greater freedom and better health,” said Annette Brüls, President of Diabetes Service and Solutions at Medtronic.

Glooko is the first mHealth and Remote Patient Monitoring diabetes platform compatible with Medtronic insulin pumps and sensors. Glooko makes this data available for people with diabetes (PWDs) to use and analyze on the go via the Glooko Mobile App by enabling users to seamlessly access their data in Glooko on their iOS and Android phones. Glooko enables clinics to sync popular diabetes devices and analyze glucose, insulin, exercise and diet trends via the Glooko Office Kiosk, enabling improved engagement with PWDs during their office visits. Glooko also makes it easy for care teams to remotely support Medtronic patients through the Glooko Population Tracker, which provides them with on-demand remote access to patient data in between visits.

“Providing users of Medtronic insulin pumps and sensors, with retrospective insights about their insulin dosing and its impact on their glucose levels on their phone can make a real difference in their overall health and outcomes,” said Rick Altinger, CEO of Glooko.

He continues, “Being the first to deliver a remote patient monitoring and mobile health solution that includes Medtronic data provides the patient population with a capability that can really have an impact.”

Glooko’s Medtronic-integrated release includes:

Glooko plans to make this integration generally available in July of 2016. Glooko will be offering a limited time promotion to purchase a discounted version of the Glooko Kiosk with Medtronic support. To sign up for the promotion, click here . Once available, Medtronic users can simply download the Glooko Mobile App from the iOS or Android App Store to get started.

Contact Glooko for more information about how you can get the Glooko Patient Mobile App or Glooko Office Kiosk for in-clinic download and analysis of Medtronic Insulin Pumps and Sensors and 50+ other devices.

MiniMed® and CareLink® are registered trademarks of Medtronic plc .

ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com, and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko.

New offering includes Glooko Personal Advisor which automatically identifies patterns for individuals and Glooko Clinical Advisor, for facilitating clinician-managed decision support during and between in-clinic visits

Mountain View, Calif. – June 10, 2016 – Glooko Inc., the leading unified platform for diabetes management, today announced its new ‘Glooko Advise’ product line, including ‘Glooko Personal Advisor’ and ‘Glooko Clinical Advisor,’ which enables both people with diabetes (PWDs) and clinicians with practical diabetes decision support. Glooko will demonstrate the new product functionalities at the 76th Annual Scientific Sessions of the American Diabetes Association from June 10 – 13, 2016 in New Orleans.

Glooko Personal Advisor aims to help PWDs better understand their retrospective diabetes data and improve daily decisions by using proprietary pattern recognition algorithms to recognize trends and deliver targeted educational content based on those trends. Personal Advisor will identify numerous trends including PWDs’ ‘Best Day’, the ‘Time of Day’ when glucose runs high or low, and ‘Summary Statistics’ that recognizes improvements or regressions in the Average BG and frequency of highs, lows, and in range readings.

“Providing this immediately understandable and novel approach for describing and interacting with diabetes data can truly illuminate learnings for people with diabetes to help them achieve their personal goals,” said Dr. David Kerr, Director of Research and Innovation at the William Sansum Diabetes Center in Santa Barbara. He continued, “without doubt the new Glooko Advise product line provides valuable and relevant tools for people with diabetes and their clinicians that will enable the achievement of the desired outcomes in diabetes care.”

Glooko Clinical Advisor will include both AACE guidelines and clinical algorithms that, once initialized and approved by a clinician, can aid the clinician to more effectively optimize diabetes therapy in the weeks or months between in-clinic appointments. Glooko will demonstrate products within Clinical Advisor that enable:

1. Mobile Insulin Dosing – Using Glooko’s Mobile Insulin Dosing system (MIDS), clinicians can configure an insulin prescription for PWDs starting on long-acting insulin using a standard or custom insulin titration method based on the AACE guidelines. After the configuration, Glooko’s Mobile App will automatically prompt, recommend and remind PWDs of insulin adjustments based on glucose readings and the insulin titration configuration defined by their clinician.

2. Insulin Pump Settings Adjustments – Glooko’s first built-in 3rd party algorithm developed by DreaMed Diabetes recommends adjustments to critical insulin pump settings, including basal rates and insulin-to-carb ratios. Through the Glooko interface and leveraging Glooko’s easy data syncing and management platform, clinicians can review DreaMed algorithm recommendations and make therapeutic regimen decisions. Within a patient record in the Glooko Population Tracker, the clinician can approve, adjust, or prevent the recommendations from being delivered to the patient.

“With the Glooko Advise product line we are executing our vision around personalized medicine where we aim to deliver improved daily decision support for people with diabetes and the teams who care for them. Clinicians clearly need additional tools to allow them to deliver more efficient care in order to handle the increasing number of PWDs on long acting insulin – Glooko’s Mobile Insulin Dosing System will meet this need” said Rick Altinger, CEO of Glooko.

DreaMed will deliver algorithms for Pump Settings adjustments by building on Glooko’s Application Programming Interfaces (APIs), which partner companies can leverage for offering FDA-regulated algorithms within Glooko Clinical Advisor. Funding for the development of this first integrated algorithm comes from a grant from the Helmsley Charitable Trust , announced earlier this year. The grant aims to facilitate and optimize insulin pump care for people with Type 1 diabetes.

Glooko Personal Advisor will be available in July 2016. The components of Glooko Clinical Advisor will be deployed for clinical studies in the second half of 2016. For more information, contact Glooko.

ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com , and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .